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The treatment of breast cancer continues to evolve at an
exceptionally rapid rate.
Understanding of the importance of tumor biology and
improvements in systemic therapy have greatly affected
management. These improvements in systemic therapy,
such as targeted therapy and immunotherapy, have resulted
in improved locoregional control and de-escalation of
locoregional therapy. Surgical treatment, as well, has
developed to lessen side effects and improve quality of life.
To understand the current role of axillary staging, the
historical perspective of surgical management must be
considered. The Halstedian view that breast cancer treatment must rely on maximum invasive locoregional therapy
was disproven following modifications to the radical
mastectomy and development of breast conserving therapy
in the mid and late 20th century. The publication of the
randomized trials by National Surgical Adjuvant Breast
and Bowel Project (NSABP) B-04 and B-06 proved that
less radical treatment of the breast is as effective as
extensive alternatives.1,2 Although the extent of the operation on the breast itself decreased, the need for an axillary
lymph node dissection (ALND) for staging and treatment
remained unchanged for nearly the entire 20th century.
Resection of involved nodes was considered essential for
cure, and removal of uninvolved nodes essential for
accurate staging. Despite the findings of NSABP B-04
showing no improvement in survival with axillary
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dissection, the procedure remained necessary to identify
patients with nodal involvement for whom adjuvant
chemotherapy was recommended.
Surgeons then began to examine the extent of axillary
surgery for accurate staging, and its role was finally challenged in the early 1990s with the development of sentinel
lymph node biopsy (SLNB). The sentinel lymph node
(SLN) hypothesis states there is a lymph node, or several
nodes, to which a breast cancer spreads if it indeed
metastasizes to the axilla. This hypothesis was proven by
performing a SLNB and then, on the same patient, completing the ALND, thus illustrating that the status of the
SLN accurately predicts the status of the entire axilla. The
first major change utilizing SLNB resulted in the omission
of traditional Level I and II ALND for the management of
patients with early-stage breast cancer who had SLNs that
were free of tumor. Axillary management was revolutionized by this simple procedure, which spared most nodenegative patients an ALND. This was first shown in a pilot
study3 and then in other prospective randomized multicenter trials.4,5 The largest of these trials was NSABP
B-32, which randomized clinically node negative patients
to SLNB alone or SLNB followed by ALND. All patients
were pathologically node negative. Locoregional recurrence rates were less than 1% in both cohorts and overall
survival (OS) and disease-free survival (DFS) were
equivalent. The differences in patient-reported outcomes
between SLNB alone and SLNB followed by ALND were
quite remarkable. ALND was shown to have statistically
significantly higher rates of lymphedema, sensory deficits,
pain, and decreased range of motion than SLNB alone.
Even before the publication of this trial, SLNB became the
treatment of choice for axillary staging in the clinically
node negative patient.5,6 This study and other randomized
trials demonstrated that overall survival, breast cancer
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specific survival, and locoregional recurrence did not differ
between women with tumor-free SLNs who undergo
ALND or no completion axillary surgery. De-escalation of
axillary surgical management with a SLNB in the node
negative patient was shown to minimize morbidity without
affecting oncologic outcomes.
SLNB alone without ALND for women with a tumorfree SLN was fairly rapidly accepted6 without results of
randomized trials. However, patients whose SLN had even
small deposits of tumor cells detected with immunohistochemistry (IHC)—now called isolated tumor cells (ITC),
defined as a tumor deposit of B0.2 mm, or micrometastases, defined as a tumor deposit [ 0.2 to B 2 mm—were
subjected to completion ALND. The prospective American
College of Surgeons Oncology Group (ACOSOG) Z0010
trial evaluated the association between survival and
metastases detected by IHC staining of SLNs and bone
marrow biopsy specimens in patients with cT1–T2, cN0
breast cancer between 1999 and 2003. In the 3326 SLNs
that were tumor-free on hematoxylin-eosin staining (H&E),
349 (10.5%) contained occult disease found with IHC. The
findings of small metastases did not affect overall survival.
Following publication of this study, IHC was no longer
recommended for evaluation of SLNs by the College of
American Pathologists.7
The prospective, randomized International Breast Cancer Study Group (IBCSG) more rigorously proved that
micrometastases were not clinically significant and did not
require treatment with ALND or alterations in systemic
therapy.8 In IBCSG 23-01, 934 women undergoing
lumpectomy or mastectomy with T1 or T2 tumors and
micrometastatic disease in C 1 SLN were randomized to
ALND or no ALND between 2001 and 2010. Among the
patients in the ALND cohort, additional involved axillary
nodes were found in 13% of patients. After a median follow-up of over 5 years, there were no significant
differences in axillary recurrence, OS or DFS between the
two groups (axillary recurrence rates of 1% in the observation group versus \ 1% in the ALND group; 87.8% in
the observation group versus 84.4% 5-year DFS in the
ALND group, p = 0.16). However, there were significantly
higher rates of sensory neuropathy (18% versus 12%, p =
0.012), lymphedema (13% versus 3%, p \ 0.0001), and
motor neuropathy (8% versus 3%, p = 0.0004) in the
ALND group compared with the group not treated with
ALND. While many major centers abandoned ALND for
patients with ITCs or micrometastases in the SLN, many
treating physicians and even academic centers were
reluctant to abandon ALND and accept the biologic concepts indicating that small metastases were not relevant for
patients with modern treatment, illustrated by ACOSOG
Z0010 and IBCSG 23-01.

The reluctance to accept omission of ALND for patients
with micrometastases in the SLN was mild compared with
the passion to complete ALND for patients with SLN
macrometastases. Although the NSABP B-04 trial showed
no survival advantage to removal or irradiating axillary
lymph nodes, axillary management in this trial was largely
ignored, primarily because of the use of adjuvant
chemotherapy for node-positive women. With 25 years of
follow-up, no improvement in survival could be demonstrated by treatment of the axilla in NSABP B-04 even
without the use of adjuvant systemic therapy and even
though most cancers were palpable and not screen-detected. Based on these results, ACOSOG Z0011 was
designed and completed. This study included women with
metastases detected with H&E who were treated with
breast conserving surgery and SLNB. The study was
designed specifically for patients undergoing breast conserving therapy for several reasons. NSABP B-04 was
criticized because patients treated with mastectomy often
had several lymph nodes included in the axillary tail. In
addition, the reluctance to de-escalate axillary surgery
exhibited by all specialties treating breast cancer was
mitigated by the use of opposing tangential radiation fields,
which were known to treat the low axilla.
ACOSOG Z0011 examined the effect of omission of
ALND in women with SLN metastases treated with contemporary adjuvant systemic therapy. Patients with clinical
T1 or T2 N0 breast cancer who underwent breast conserving surgery and were found to have one or two positive
SLNs were randomized to ALND versus no further axillary
surgery. Both micrometastases and macrometastases were
allowed in this trial. In the SLNB alone cohort, 44.8% had
micrometastases while 55.2% had macrometastases. All
patients were to be treated with whole breast radiation and
adjuvant systemic therapy.9 After 10 years of follow-up,
this trial showed no significant difference in axillary
recurrence (1.5% in observation only versus 0.5% in
ALND, p = 0.28) or distant disease-free survival rates
(80.2% in observation versus 78.2% in ALND, p = 0.32).10
ACOSOG Z0011 demonstrated that SLNB alone is as
effective as ALND for selected patients with early node
positive breast cancer undergoing breast conserving therapy and adjuvant systemic therapy.
ACOSOG Z0011 was not the only trial to demonstrate
that ALND could be omitted for patients with involved
SLNs. Equivalence in local control with axillary radiation,
instead of ALND, in patients with B 3 positive SLNs was
later proven in the AMAROS (2001–2010) and OTOASOR
(2002–2009) trials.11,12 In both trials, cN0 women who
were found to have 1–3 positive SLNs were randomized to
ALND or axillary radiation. Axillary radiation was not
associated with a statistically significant higher risk of
axillary recurrence than ALND in either study. ALND was,
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however, shown to result in higher rates of lymphedema
than axillary radiation in the AMAROS trial. All publications to date fail to show any association between axillary
surgery and breast cancer-related outcomes. Although
AMAROS showed decreased rates of lymphedema at 5
years, longer follow-up has not been published.
Complete omission of axillary staging in the elderly was
examined in the Cancer and Leukemia Group B (CALGB)
9343 trial. In addition to evaluating the role of adjuvant
radiation, it also allowed for evaluation of the role of
ALND. From 1994 to 1999, CALGB 9343 enrolled
patients 70 years of age and older who underwent a margin
negative lumpectomy with cT1N0, hormone receptor (HR)
positive breast cancer. While ALND was allowed, it was
not encouraged. Patients were randomized to either
tamoxifen plus whole breast irradiation or tamoxifen alone.
Among the 62% of patients who did not undergo ALND,
there were no axillary recurrences in the tamoxifen plus
radiation group and 6 of 200 (3%) developed an axillary
recurrence in the tamoxifen only group. Based on these
results, the use of nodal staging in this population was
questioned unless it would change systemic therapy recommendations.13,14 In IBCSG 10-93, postmenopausal
women C 60 years old with cT1–T3, cN0 breast cancer
were randomized to breast surgery followed by tamoxifen
with or without ALND. Of the 473 patients enrolled in this
trial from 1993 to 2002, 45% underwent mastectomy, 33%
underwent lumpectomy with radiation therapy, and 23%
underwent lumpectomy without radiation. Locoregional
recurrence was not significantly different among the
groups—reported in 3% of the patients who did not
undergo ALND and 1% of those who did. Like the findings
of other trials, 28% of the patients who underwent ALND
were found to be node positive. It is again safe to assume
that 28% of the patients who did not have an ALND would
have also been pathologically node positive, but a higher
axillary failure rate was not identified.15
Due to the lack of survival benefit with nodal staging
and the competing co-morbidities found in the older patient
population with breast cancer, multiple other retrospective
studies have shown that ALND can be safely deferred in
clinically node negative women 70 years of age and older
with HR- positive breast cancer.16–19 Axillary surgery may
be omitted for selected patients, including women 70 years
or older with early stage, clinically node negative, HRpositive breast cancer, women with severe co-morbidities
for whom decisions for adjuvant therapy will not change
despite axillary status, and perhaps those with histologic
subtypes for whom the risk of nodal metastases is extremely low. The Society of Surgical Oncology Quality
Committee subsequently initiated the Choosing Wisely
Guidelines for breast cancer in 2016, in which routine use
of SLNB in this group of women is discouraged.20 As these

patients are unlikely to have chemotherapy recommended,
regardless of nodal status, axillary surgery appears unnecessary. Since publication of these guidelines, it has been
accepted that the benefit of nodal staging in this cohort is
minimal and omission is deemed safe.
However, the recent publication of monarchE has
challenged this, and may render the need for axillary
staging in a group of women in whom its omission was
accepted. The monarchE clinical trial randomized 5637
patients to adjuvant endocrine therapy for 5 years with or
without abemaciclib for 2 years. Patients were eligible if
they had four or more positive lymph nodes or 1–3 positive
lymph nodes and high-risk features. The study demonstrated a 29% reduction in developing an invasive diseasefree survival event for patients treated with abemaciclib.
Notably, 57% of patients were post-menopausal.21 The
results from monarchE align women with HR-positive
breast cancer in a category similar to HER2-overexpressing
tumors and triple negative breast cancer (TNBC), whereby
understanding nodal status contributes to survival. Furthermore, the results of monarchE may prompt the need for
ALND in more women with HR-positive breast cancer and
a positive SLN to determine the need for abemaciclib.
Additional studies may create additional dilemmas for
surgical staging.
If there is pathologic nodal involvement, studies have
demonstrated that axillary staging affects adjuvant radiation and systemic therapy decisions. Chapgar et al. utilized
the NCDB to evaluate women 70 years of age and older
with clinically node negative, HR-positive breast cancer.22
They found that 15% of patients had pathologically
involved lymph nodes. These patients were more likely to
receive chemotherapy, hormone therapy, and adjuvant
radiation (post-lumpectomy and post-mastectomy). This
was independent of tumor size, grade, patient age, and comorbidities. The results support the continued use of
axillary staging in elderly women in whom adjuvant
treatment decisions, such as the use of whole breast radiation therapy, depend on its findings.
The status of the axillary lymph nodes historically
played a significant role in determining need and extent of
adjuvant systemic therapy. In recent years, however,
genomic assays have been developed to predict prognosis
and response to adjuvant systemic chemotherapy and the
importance of anatomic staging appears to be diminished,
with tumor biology now at the forefront.23,24 The results
from the RxPONDER trial demonstrated no benefit for
chemotherapy in post-menopausal women with HR-positive tumors and recurrence score (RS) of 25 or lower.
However, all pre-menopausal women with nodal metastases in 1–3 SLNs were shown to benefit from
chemotherapy.24 Thus, nodal staging remains imperative in
pre-menopausal women with HR-positive breast cancer,
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but may not be necessary for clinically node negative
postmenopausal women with low recurrence score or
elderly women with small HR-positive tumors. Elderly
women with larger tumors or palpable nodes still require
axillary staging. In women with a clinically negative axilla,
the axillary operation itself has no measurable impact on
survival. However, nodal staging often influences systemic
therapy decisions and provides information contributing to
survival. Genomic assays provide useful information but
cannot completely replace the knowledge gained from
axillary staging. Nodal status is necessary to inform adjuvant treatment decision making, specifically when to
escalate and de-escalate therapy. This can be seen across
all biological subtypes of breast cancer.
In women with HER2-overexpessing tumors, the APT
study demonstrated the safety of systemic therapy deescalation. Between 2007 and 2010, 410 women with
HER2-overexpressing tumors that were 3 cm or less and
had pathologically uninvolved lymph nodes (though after
2009 a single micrometastases was permitted) who were
administered adjuvant paclitaxel for 12 weeks and trastuzumab for 9 months had excellent results despite deescalated therapy. With reported 7 years of follow-up,
overall and disease-free survival were over 95%.25 For
women with HER2-overexpressing tumors that are 3 cm or
smaller, axillary surgery permits de-escalation of systemic
therapy if the SLN is pathologically tumor-free.
The presence of residual disease in the breast or axilla in
patients with HER2-overexpressing tumors or triple negative breast cancer (TNBC) after neoadjuvant chemotherapy
(NAC) prompts the need for escalated adjuvant therapy.
The KATHERINE trial, conducted between 2013 and
2015, randomized 1486 women with HER2-overexpressing
tumors and residual disease following NAC to trastuzumab
or TDM-1. After 40-months of follow up, TDM-1 resulted
in a 50% improvement in disease free survival.26 The
CREATE-X study (2007–2012) randomized 887 women
with TNBC who had residual disease following NAC to
capecitabine or no further therapy. Adjuvant capecitabine
was found to prolong disease-free survival and overall
survival in this cohort.27 The benefit of adjuvant TDM-1
and capecitabine following NAC for women with HER2overeexpressing tumors and TNBC, respectively, mandates
axillary staging to assess for residual nodal disease after
NAC. No imaging modality has been shown to reliably
identify residual disease after NAC.
Two areas for which there is no consensus for management warrant further attention: (1) the node positive
patient after neoadjuvant chemotherapy and (2) observation versus SLNB in all clinically node negative patients.
There are new data on the horizon that will hopefully shed
some light on these conundrums. First and foremost, the
results of the Alliance A11202 trial are long awaited. In

this phase III clinical trial, patients who are persistently
node positive following NAC are randomized to regional
nodal irradiation (RNI) plus axillary radiation or RNI plus
ALND.28 Expected trial completion is January 2024, and
the findings will undoubtedly enhance understanding of the
management of the node positive axilla after NAC. Until
the results of this study are available, if a patient is node
positive after NAC, ALND is recommended. Second, the
ongoing SOUND (Sentinel node versus Observation after
axillary UltraSouND), INSEMA (Intergroup-SentinelMamma), and BOOG 2013-08 trials are comparing SLNB
to observation in clinically node negative patients.29–31 The
reported sensitivity and specificity of axillary ultrasound
ranges from 26.4% to 94% and 53% to 98.1%, respectively.32,33 Without complete data from the trials
mentioned above to guide treatment recommendations,
axillary imaging cannot replace surgical nodal staging.
Therapy of breast cancer should change only after scientific trials demonstrate an improvement in outcome. This
is a lesson previously learned when randomized studies
dispelled the myth that high doses of chemotherapy followed by bone marrow autotransplantation was the
preferred treatment for women with recurrent or advanced
breast cancer.34 Currently, there is no Level 1 evidence to
support the routine omission of axillary surgery for most
women with breast cancer. Genomic testing and randomized trials did not eliminate axillary surgery. They only
refined its indications.
CONCLUSIONS
These dramatic changes in breast cancer management
and our understanding have led some to suggest that axillary staging is obsolete. While it appears true that axillary
operations themselves may not improve survival for most
patients with early breast cancer, they remain necessary to
select therapy that may be lifesaving or to permit deescalation of treatment. There are no biologic predictors of
nodal metastases, and no imaging modality is considered
sensitive or specific enough to permit the omission of
surgical axillary staging, which can lead to alterations in
treatment. While prospective, randomized studies demonstrated that ALND is not necessary for some women with
limited SLN metastases, these studies do not render axillary surgery obsolete. In these studies, all patients had a
SLNB to determine axillary status. Furthermore, the impact
of omission of ALND remains unproven in women with
palpable lymph nodes, women undergoing operation with
tumors greater than 5 cm or with three or more positive
sentinel lymph nodes, women with gross extranodal
extension, women for whom radiation is contraindicated,
or women with residual nodal metastases following NAC.
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In 2022, SLNB should be performed for nearly all
clinically node negative patients. Axillary staging may be
omitted for some patients, including those undergoing
prophylactic mastectomy or those with ductal carcinoma
in situ (DCIS) treated with breast conserving surgery.
Axillary staging may also be omitted when axillary status
is irrelevant and will not influence systemic therapy, such
as patients 70 years or older with early stage, HR-positive
breast cancer or patients with severe co-morbidities in
whom adjuvant therapy will not be administered.
While ongoing studies may provide some answers to
axillary management in different clinical scenarios, they
may also lead to the possibility of omission of an axillary
operation in certain groups of patients and to additional
questions. Currently, axillary surgery is necessary for most
women with breast cancer. There is no method to detect
axillary metastases as effectively as axillary operation.
SLNB remains the cornerstone of axillary management. It
can only be omitted in a small number of selected patients.
It is not outmoded or obsolete and cannot be discarded.
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